Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease caused by the accumulation of a surfactant (proteins and lipids) accumulated in small air bags of the lung, called alveoli, which interfere with breathing. PAP condition occurs in 6 individuals per million and is considered an orphan disease.
Complete report available at www.marketreportsonline.com/699362.html.
Pulmonary surfactant is produced by the body in healthy people and patients with PAP, which is a mixture of phospholipids and synthesized proteins.
These surfactants form cell lines to prevent the collapse of the pulmonary membranes by reducing the surface tension. This pulmonary surfactant must be constantly replaced to maintain the active and functional layer and to prevent excessive layering.
The exact reason for the accumulation of excess surfactants is unknown. This requires a signal and messenger molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) to stimulate alveolar macrophages to work properly and maintain a normal level of surfactant in the cells.
This process of maintaining a stable state is known as homeostasis and requires that GM-CSF stimulate alveolar macrophages to remove excess surfactant.
Access a copy of this research report at www.marketreportsonline.com/contac…e.php?name=699362.
Treatment of PAP depends on the form of PAP and age of a patient with PAP and severity of the disease. WLL is a standard treatment for PAP and the only treatment which has shown improved symptoms and oxygenation in patients.
Another treatment of PAP includes using recombinant granulocyte colony stimulating factor (GM-CSF) which is given by nose or with a subcutaneous injection which is not approved yet.
The global PAP market is expected to show significant growth after the introduction of the molgradex drug in 2020. The growth of market will mainly be driven by huge unmet demand, increasing male population, rising middle-aged population and increasing health expenditure.
However, the growth of the market will be hindered by the absence of effective diagnostics and costly drugs.
This research report “Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on the US, Europe, and Japan region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report.
A key upcoming player in the market i.e. Savara Inc. is being profiled along with its key financials and strategies for growth.
The report contains a comprehensive analysis of the global PAP market along with the study of the regional markets.
Category: Market Research Publishers and RetailersCompany about: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.